In addition, many biomarkers have been proposed to determine the therapeutic effect of pembrolizumab treatment, such as tumor size, albumin, lymphocyte count, and lactate dehydrogenase level [41, 46–49], however, none of these biomarkers accurately predicted the efficacy of pembrolizumab. This evidence concerns the gene ALB and neoplasm.